Efficacy, Immunogenicity, and Safety of Two Doses of a Tetravalent Rotavirus Vaccine RRV-TV in Ghana With the First Dose Administered During the Neonatal Period | Zendy

George Armah | Zendy; Albert Z. Kapikian | Zendy; Timo Vesikari | Zendy; Nigel A. Cunliffe | Zendy; Robert M. Jacobson | Zendy; D. Bruce Burlington | Zendy; Leonard P. Ruiz | Zendy

Open Access

Efficacy, Immunogenicity, and Safety of Two Doses of a Tetravalent Rotavirus Vaccine RRV-TV in Ghana With the First Dose Administered During the Neonatal Period

Author(s) -

George Armah,

Albert Z. Kapikian,

Timo Vesikari,

Nigel A. Cunliffe,

Robert M. Jacobson,

D. Bruce Burlington,

Leonard P. Ruiz

Publication year - 2013

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jit174

Subject(s) - rotavirus vaccine , medicine , rotavirus , placebo , serotype , population , immunogenicity , pediatrics , reoviridae , diarrhea , intussusception (medical disorder) , dosing , vaccination , virology , immunology , environmental health , surgery , antibody , alternative medicine , pathology

Oral rhesus/rhesus-human reassortant rotavirus tetravalent vaccine (RRV-TV) was licensed in 1998 but withdrawn in 1999 due to a rare association with intussusception, which occurred disproportionately in infants receiving their first dose at ≥90 days of age. This study examined RRV-TV for the prevention of rotavirus gastroenteritis (RV-GE) in Ghana, West Africa, with infants receiving the first dose during the neonatal period and the second before 60 days of age.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research